Next Article in Journal
Effects of Astragaloside IV and Formononetin on Oxidative Stress and Mitochondrial Biogenesis in Hepatocytes
Previous Article in Journal
HGS Promotes Tumor Growth, Whereas the Coiled-Coil Domain and Its Oligopeptide of HGS Suppress It
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Cellular Signaling of Amino Acid Metabolism in Prostate Cancer

1
School of Biology and Biological Engineering, South China University of Technology, University Town, Guangzhou 510006, China
2
Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA 5042, Australia
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2025, 26(2), 776; https://doi.org/10.3390/ijms26020776
Submission received: 15 December 2024 / Revised: 14 January 2025 / Accepted: 15 January 2025 / Published: 17 January 2025
(This article belongs to the Section Molecular Endocrinology and Metabolism)

Abstract

Prostate cancer is one of the most common malignancies affecting men worldwide and a leading cause of cancer-related mortality, necessitating a deeper understanding of its underlying biochemical pathways. Similar to other cancer types, prostate cancer is also characterised by aberrantly activated metabolic pathways that support tumour development, such as amino acid metabolism, which is involved in modulating key physiological and pathological cellular processes during the progression of this disease. The metabolism of several amino acids, such as glutamine and methionine, crucial for tumorigenesis, is dysregulated and commonly discussed in prostate cancer. And the roles of some less studied amino acids, such as histidine and glycine, have also been covered in prostate cancer studies. Aberrant regulation of two major signalling pathways, mechanistic target of rapamycin (mTOR) and general amino acid control non-depressible 2 (GCN2), is a key driver of reshaping the amino acid metabolism landscape in prostate cancer. By summarising our current understanding of how amino acid metabolism is modulated in prostate cancer, here, we provide further insights into certain potential therapeutic targets for managing prostate cancer through metabolic interventions.

1. Introduction to Prostate Cancer (PCa)

PCa ranks among the top five cancers in terms of global new cancer cases, and it is the second most prevalent malignant tumour and the leading cause of cancer-related mortality in males [1]. The incidence of this cancer markedly rises with age [2], and the prognosis varies depending on the timeliness of diagnosis and intervention. For patients with distant metastatic PCa, the 5-year survival rate is merely 30% [3]. Given that the growth and proliferation of prostate epithelial cells are dependent on androgens [4], androgen deprivation therapy (ADT) becomes the front line of therapeutic interventions, which targets either the gonadotropin-releasing hormone or the androgen receptor (AR). While ADT can initially benefit the health condition of PCa patients, unfortunately, most of them will unavoidably progress to refractory castration-resistant prostate cancer (CRPC), which is fatal [5]. Therefore, there is still an urgent need for a comprehensive understanding of the key factors that contribute to disease progression for the next generation of targeted strategies.
Substantial advancements have been made in recent decades in understanding the molecular mechanisms that drive PCa development, especially PCa-specific metabolic alterations. PCa cells adapt to rapid growth and survival by altering the homeostasis of key metabolic processes, with glucose metabolism, lipid metabolism and amino acid metabolism (AAM) being the most frequently remodelled core pathways. In this review, we aim to summarise our current understanding of how AAM is dysregulated in PCa in comparison to physiological conditions, especially focusing on key altered genes, amino acid residues (glutamine, tryptophan, leucine, arginine, methionine, histidine, serine and glycine) and amino acid signalling pathways (mTOR and GCN2).

2. Amino Acid Metabolism in PCa

Amino acids play roles extending beyond mere support for rapid protein synthesis and cellular proliferation in cancer cells; they also serve as a vital resource for tumour invasion, metastasis and immune evasion. It is well established that cancer cells are heavily addicted to several key amino acids for tumorigenesis, such as glutamine, methionine and arginine [6], and a similar dependency has been observed in PCa [7,8,9,10,11]. Metabolomic analyses of PCa patient serum and tissue samples have also revealed alterations in the levels of other amino acids. For example, a declining trend for histidine in the serum of PCa patients was observed when benign hyperplasia progressed from to primary and metastatic cancer and CRPC [12]. In the following sections, we will provide an overview of the reshaped AAM and its impacts on cell fate in PCa.

2.1. Glutamine

Glutamine, the most abundant amino acid in the bloodstream [13], is important for sustaining cancer cell growth and proliferation. Many proliferating cancer cells are addicted to glutamine as a crucial energy source and a critical biosynthesis precursor. An elevated glutamine metabolism has been associated with advanced PCa [14]. Glutamine and glutamic acid are markedly reduced in urine samples from PCa patients compared to those from healthy subjects [15,16].
The tricarboxylic acid (TCA) cycle serves as an essential pathway for cellular energy metabolism, occurring within the mitochondria, where the pyruvate generated from glycolysis is converted into acetyl-CoA and subsequently utilised to produce carbon dioxide, water and energy. In healthy prostate epithelial cells, the glucose-derived TCA cycle is disrupted at the citrate synthesis step due to the Zn2+ accumulated within the cells [17]. Hence, healthy prostate epithelial cells rely on glycolysis as their primary pathway for energy production; however, primary PCa exhibits a distinct glucose flux, characterised by enhanced oxidative phosphorylation and a limited rate of glycolysis [18]. This has been suggested to be the consequence of the decreased concentration of Zn2+ and the restored activity of aconitase [19,20]. Interestingly, as PCa develops, the contribution of glucose to the mitochondrial activity reduces, evidenced by increased aerobic glycolysis, known as the Warburg effect [21,22,23]. Despite the diminished glucose availability within the mitochondria, the activity of the TCA cycle remains elevated, as it is predominantly driven by glutamine metabolism. In the mitochondrion, glutamine is firstly converted into glutamate by glutaminase (GLS), which is then further processed by either glutamate dehydrogenase (GDH) or transaminase reactions to produce α-ketoglutarate (α-KG), an intermediate that feeds into the TCA cycle. The less catalytically active isoform of GLS1, KGA, predominates in early hormone-sensitive PCa. However, as the disease progresses into CRPC and small cell neuroendocrine carcinoma, the expressed GLS1 isoform shifts to a more enzymatically active and AR-independent GAC variant, enabling advanced PCa cells to preferentially utilise glutamine over glucose to fuel the TCA cycle [13,24]. This isoform switch forms the molecular basis for the high dependency of advanced PCa on glutamine rather than glucose. The robust enzymatic activity of the GLS1-GAC isoform enables tumour cells to channel greater amounts of glutamine into the TCA cycle, thereby enhancing the proliferative capacity of the cancer cells and driving more aggressive cellular behaviour [25]. By inhibiting GLS1 activity, particularly the GLS1-GAC isoform, it may be possible to effectively restrict the glutamine utilisation in PCa cells, thereby impeding their growth and proliferation.

2.2. Tryptophan

Tryptophan, an essential amino acid, serves as a precursor to serotonin and melatonin and contributes to nitric oxide synthesis, gut microbiota modulation and immune regulation, influencing immune responses and stress resilience. The significance of tryptophan in PCa has been extensively studied, with reports indicating that the tryptophan metabolism is significantly reduced in PCa patients compared to that in healthy controls [26,27].
Tryptophan metabolism plays a complex role in PCa metabolism, i.e., increased levels of tryptophan can either be beneficial or detrimental to PCa cells. High concentrations of tryptophan in prostate tumours lead to elevated levels of kynurenine [28], a terminal product of tryptophan metabolism which binds to and activates the aryl hydrocarbon receptor (AHR). The AHR is a transcription factor that regulates the expression of genes which promote cell growth, survival, DNA synthesis and cell cycle regulation, for example, MYC and CCND1 (which encodes cyclin D1) [29]. When it is activated, the AHR translocates to the nucleus, where it binds to the DNA and initiates the transcription of downstream genes. Additionally, kynurenine suppresses T-cell activity, offering PCa cells an opportunity for immune evasion and thereby facilitating PCa cell survival and metastasis [30].
In contrast, it has also been demonstrated that tryptophan can be proapoptotic and antiproliferative for PCa cells. Several metabolites of tryptophan metabolism, such as 3-Hydroxyanthranilic acid, have been shown to inhibit PCa cell proliferation, potentially through mechanisms involving the suppression of protein and DNA synthesis. High tryptamine levels are known to induce apoptosis through evoking the intrinsic caspase cascade [31]. Further studies are still needed to dissect why dysregulation of the tryptophan metabolism pathway is both pro- and anti-PCa progression. Rebalancing the flux of tryptophan into different metabolites may be helpful for controlling cancer growth.

2.3. Leucine

Leucine is an essential amino acid that serves as a crucial energy source for tumour cell growth and survival. Many cancer cells rely on leucine to meet their rapid proliferation and metabolic demands. Inhibiting leucine uptake can often substantially reduce tumour cell proliferation and tumour growth [32]. In PCa research, leucine and its derivatives are often used as radiotracers for precise tumour localisation and for assessing the systemic tumour burden [33].
Leucine metabolism undergoes significant reprogramming in PCa. Leucine is catabolised within the cells to produce various metabolites, such as α-ketoisocaproate, that enter the TCA cycle. These metabolites provide energy and intermediate substrates for cancer cells [32,33]. Additionally, as a ketogenic amino acid, leucine is extensively consumed in metastatic PCa cells undergoing metabolic reprogramming, which induces a pronounced Warburg effect, further enhancing leucine’s glycolytic potential and supporting the maintenance of the stem-like phenotype of PCa stem cells [34].
Leucine metabolites are implicated in modulating the tumour microenvironment by influencing inflammatory responses and immune cell functions to impact on the progression of PCa [35]. Leucine is also a key activator of mTOR complex 1 (mTORC1), a main driver of mRNA translation in cancer cells. Please refer to Section 3.1 for more details.

2.4. Arginine

PCa is considered a typical immune-“cold” tumour, as PCa cells employ various mechanisms to evade immune surveillance, with intracellular arginine metabolism being one of the immunoregulatory factors. Arginine is a semi-essential amino acid that can be metabolised by arginase (ARG) to produce ornithine and urea or converted by inducible nitric oxide synthase (iNOS) to generate nitric oxide and citrulline [36,37]. ARGII and iNOS, respectively, are overexpressed in PCa tissue [38,39]. Enhanced arginine degradation inhibits the function of macrophages and T lymphocytes within the prostate tumour microenvironment and thereby impedes immune responses [37]. Evidence supports that inhibiting the activity of ARG and iNOS using specific inhibitors (N-monomethyl-L-arginine for iNOS and N-hydroxy-L-arginine for ARG) allows tumour-infiltrating lymphocytes to recover their responsiveness to tumour antigens [40].
Moreover, arginine starvation led to mitochondrial dysfunction in 22Rv1 and PC3 cells, evidenced by alterations in the mitochondrial morphology and the increased production of reactive oxygen species [41,42]. DNA damage and excessive autophagy are known to be associated with the silencing of nuclear-encoded mitochondrial genes, including those implicated in oxidative phosphorylation and nucleotide synthesis. Arginine acts as an epigenetic regulator of TEAD-4, a member of the mitochondrial transcription factor family that plays an important role in driving the expression of mitochondrial genes involved in oxidative phosphorylation, to enhance oxidative phosphorylation in PCa cells [43,44].

2.5. Methionine

Methionine is an essential amino acid involved not only in the initiation of protein synthesis but also in various cellular biochemical reactions, including biological methylation, antioxidation and polyamine synthesis. Methionine addiction, also known as the Hoffman effect, is one of the most characteristic metabolic reprogramming activities in cancer cells. This implies that cancer cells are unable to grow or proliferate under methionine deprivation, whereas non-cancerous cells can utilise homocysteine to replace methionine and remain unaffected [45]. Therefore, methionine restriction is considered to be a promising anti-cancer strategy [46]. Methionine restriction was able to markedly inhibit the growth of PC-3 and DU145 (androgen-insensitive) cells in vitro; meanwhile, LNCaP (androgen-sensitive) cells exhibited a weaker dependence on methionine [47], implying an even more increased demand for methionine in advanced, AR-null PCa. Furthermore, the depletion of methionine was shown to have apoptotic and anti-invasion effects on PC-3 and DU145 cells [9], and mitochondrial damage was the key factor in cell death, with the suppressed integrin/FAK pathway accountable for their inhibited invasion [9,48,49,50]. Clinical studies have demonstrated that for patients with advanced PCa and bone metastases, methionine deprivation therapy (MDT) resulted in a reduction in PSA levels [51,52]. These findings highlight the great therapeutic potential of MDT in the design of future anti-PCa therapies.
Metabolomics and transcriptome analyses have revealed significant alterations in the methionine metabolism in PCa tissue samples [53]. Methionine is able to be metabolised into S-adenosylmethionine (SAM) by methionine adenosyltransferases ((MATs) including MAT2α and MAT2β), which are encoded by MAT2A and MAT2B, respectively, in prostate tissues. MAT2A and MAT2B are highly expressed in PCa [54]. Overexpressed MAT can provide a survival advantage for cancer cells [55]. Two inhibitors of MAT2α, PF-9366 and AG-270, could significantly suppress VCaP cell growth in a spheroid assay, as well as enhancing the effectiveness of enzalutamide for CRPC in both in vivo and in vitro models [56]. Exogenous SAM could also be a promising PCa-suppressing agent, as evidenced by the pronounced reduction in PC-3 cell proliferation, migration and invasion after treatment with SAM [57]. Further investigations have elucidated the potential mechanisms of its anti-cancer effect on PCa cells. For example, SAM inhibited the activation of ERK and STAT3 in both PC-3 and DU145 cells, and the miR-34a/b-MAT2α/MAT2β signalling axis could play a role in this regulation [54,58]. SAM could also downregulate the transcription of oncogenes by acting as a methyl group donor for DNA methylation, thereby preventing PC-3 cell growth [59,60].

2.6. Histidine

Histidine is one of the least abundant amino acids in the human body. Apart from its direct participation in the process of protein synthesis, it can also be converted into urocanate for glutamate metabolism, while the small remaining portion is further metabolised into carnosine, histamine and other histidine derivatives. Notably, histamine plays a key role in inflammation and immunity [61]. In mouse prostate tissues, a high-fat diet induced the expression of Hdc, which encodes histidine decarboxylase, and led to a significant increase in histamine levels and cytokine expression [62]. As a receptor antagonist for histamine signalling, fexofenadine alleviated the inflammation stimulated using histamine in a murine PCa model and inhibited tumour growth in vivo, implying that targeting histamine could be a novel strategy against obesity-induced prostate carcinogenesis.

2.7. Serine

Serine, a non-essential amino acid, can be acquired from extracellular sources via the serine–lysine–cysteine–threonine transporter (ASCT) or synthesised endogenously from glycolytic intermediates, such as 3-phosphoglycerate or glycine. Serine is fundamental to the growth and proliferation of cancer cells [63]. Although the human body can synthesise most serine through biosynthetic pathways [64], rapidly proliferating cancer cells still require external serine sources to meet their high metabolic demands. The plasma serine levels are significantly elevated in PCa patients, particularly those with a Gleason grade higher than 6 [65,66], and treatment with ASCT inhibitors has been shown to suppress the growth of LNCaP and 22Rv1 cells [67]. However, due to real-life challenges such as unavoidable dietary sources of serine and the fact that the transport of other amino acids (i.e., lysine, cysteine and threonine) also relies on ASCT, exogenous serine restriction remains unrealistic as an anti-PCa strategy [68].
Serine metabolism is intricately connected to various critical metabolic activities, attracting considerable interest from cancer researchers. For example, the Serine–Glycine–One-Carbon (SGOC) metabolic network is essential for the biosynthesis of proteins, lipids and nucleic acids, which are required for cell growth and proliferation. Upregulation of the SGOC network is crucial for sustaining rapid cancer cell proliferation in several malignancies, including neuroendocrine PCa (NEPC) [69]. Recent studies have revealed several key drivers of PCa within the SGOC network, including phosphoglycerate dehydrogenase (PHGDH) and serine hydroxymethyltransferase (SHMT1/2) [70,71]. PHGDH, the initial and rate-limiting enzyme in the SGOC pathway, is highly expressed in breast cancer [72], bladder cancer [73] and PCa [69]. It is also implicated in the drug resistance mechanisms across various cancers [74]. Wang et al. demonstrated that PHGDH knockdown could suppress the growth of enzalutamide (AR antagonist)-resistant CRPC cells and restore their sensitivity to enzalutamide [75]. SHMT1/2, a set of isoenzymes responsible for catalysing the conversion of serine into glycine in the cytoplasm and mitochondria, promoted tumorigenesis in breast and ovarian cancer and PCa [76]. The expression of the SHMT2 gene was upregulated in primary prostate tumours [77]. SHMT2 promoted the proliferation and metastasis of PCa by affecting energy metabolism and promoting the epithelial–mesenchymal transition (EMT). Diminished SHMT2 expression in invasive PCa cells resulted in enhanced cell viability, migration and upregulation of genes related to the EMT through MAPK pathway activation [78]. Additionally, IL-6-stimulated inflammatory responses evoked oxidative stress and increased lactate fermentation via the STAT3/SHMT2/PKM2 pathway during the early stage (Gleason score: 6) of PCa. As the disease advances, persistent inflammatory states lead to oxidative stress, activating the STAT3/HIF-1α/PKM2 axis to sustain the Warburg effect, a phenomenon corroborated by comparing PCa tissue samples from patients with different Gleason scores [79].

2.8. Glycine

Glycine plays a crucial role in mRNA translation and the synthesis of small biomolecules such as creatine, purines and glutathione. The first metabolite profiling of cancer derived from the NCI-60 cancer cell line screen revealed that cancer cells exhibit significant dependency on glycine [80]. Remarkable differences in the serum and urine glycine levels were observed in PCa patients compared with healthy individuals [81,82,83,84,85]. Rapidly proliferating cancer cells exert a high demand on glycine metabolism [80,86], although this may be an indirect effect owing to the conversion of glycine into serine [63]. Recent studies have indicated that the mitochondrial glycine cleavage system (GCS) plays an important role in cancer [87,88,89,90], providing new insights into the effects of dynamic changes in glycine metabolism in cancer progression. GCS is the primary enzymatic system for glycine catabolism in the human body [91], wherein GLDC, which encodes the glycine decarboxylase protein, has been found to be significantly upregulated in various cancers, including PCa [92,93,94]. The overexpression of GLDC in 22RV1 cells enhanced glycolytic metabolism and played a critical role in cell invasion, metastasis and immune evasion [95].
Aminoacyl-tRNA synthetases (ARSs) are essential enzymes in the translation process that convert genetic information into proteins. They are responsible for attaching amino acids to their corresponding tRNA molecules to form aminoacyl-tRNAs. An increasing body of evidence indicates that ARSs are not only pivotal for protein biosynthesis but also play additional roles in other physiological and pathological cellular processes [96]. For instance, the aberrant expression or post-translational modification of ARSs can affect cancer angiogenesis, invasion and metastasis [97,98]. Elevated levels of GARS, HARS, WARS and KARS have been detected in PCa cells in response to androgens [99,100]. GARS expression was positively correlated with PCa cell cycle progression, proliferation, migration and their ability in immune escape [101,102].
While focusing on these metabolic changes in PCa, we noticed that the dysregulation of certain genes’ expression is involved in alterations in AAM paradigms (Figure 1 and Table 1). In the following sections, we will extend the discussion of the aberrant transcriptional regulation of key genes implicated in AAM, which can be leveraged to design potential anti-PCa treatment strategies.
Figure 1. Differentially expressed genes related to AAM in PCa. (a) The volcano plot illustrates differentially expressed genes that were identified from the TCGA RNA-seq data of PCa patients. (log2FoldChange (log2FC) ≥ 1, q < 0.05). The green dots indicate genes that are downregulated in PCa tissues, while the red ones indicate genes that are upregulated in the disease. (b) The same as A but genes associated with AAM are coloured in orange. The top 5 most up- or downregulated AAM-related genes are labelled. (c) Differently expressed genes implicated in AAM (AA_DEGs) in primary PCa tissues were identified according to the GEPIA [103], CPGEA [104] and TCGA [105] databases, and a total of 29 genes were identified which were differentially expressed in at least two databases. (d) Heatmap illustration of the 29 AA_DEG genes mentioned in (c). (e) KEGG enrichment analysis of the AA_DEGs.
Figure 1. Differentially expressed genes related to AAM in PCa. (a) The volcano plot illustrates differentially expressed genes that were identified from the TCGA RNA-seq data of PCa patients. (log2FoldChange (log2FC) ≥ 1, q < 0.05). The green dots indicate genes that are downregulated in PCa tissues, while the red ones indicate genes that are upregulated in the disease. (b) The same as A but genes associated with AAM are coloured in orange. The top 5 most up- or downregulated AAM-related genes are labelled. (c) Differently expressed genes implicated in AAM (AA_DEGs) in primary PCa tissues were identified according to the GEPIA [103], CPGEA [104] and TCGA [105] databases, and a total of 29 genes were identified which were differentially expressed in at least two databases. (d) Heatmap illustration of the 29 AA_DEG genes mentioned in (c). (e) KEGG enrichment analysis of the AA_DEGs.
Ijms 26 00776 g001
Table 1. Functional annotation of the differentially expressed AAM-related genes in PCa.
Table 1. Functional annotation of the differentially expressed AAM-related genes in PCa.
Amino AcidGene SymbolFull NameBiological FunctionAlteration in PCaEffects on PCaReference
ArginineCKMCreatine kinase, M-typeCatalyses the reversible transfer of a phosphate group between ATP and various phosphogensaDecrease in both trancription and protein levels;
high expression was correlated with prolonged relapse-free survival
[106]
AspartateFOLH1Folate hydrolase 1Acts as a glutamate carboxypeptidase and plays a key role in folate metabolism by breaking down folate and folate derivativesbKnown as the prostate-specific membrane antigen and highly expressed;
a diagnostic biomarker
[107,108]
LeucineMCCC2Methylcrotonyl-CoA carboxylase subunit 2Engaged in leucine and isovaleric acid catabolismAs an androgen-regulated gene;
involved in carcinogenesis by upregulating GLUD1 in the GLUD1-p38 MAPK signalling axis
[109,110]
LysineEZH2Enhancer of zeste 2 polycomb repressive complex 2 subunitResponsible for trimethylating histone H3 on lysine 27, i.e., yielding H3K27me3, a histone modification that represses gene transcriptionOverexpression promoted tumour proliferation, metastasis, drug resistance and poor prognosis[111,112,113,114]
MECOMMDS1 and EVI1 complex locusEncodes an oncoprotein (transcription factor) known as Evi-1, regulating the gene expression during hematopoiesis and developmentOverexpression contributed to docetaxel resistance in PC3 cells[115]
ProlineOATOrnithine aminotransferaseCatalyses the reversible interconversion of L-ornithine and 2-oxoglutarate into L-glutamate semialdehyde and L-glutamateRepressed by AR knockdown in C4-2B cells[116]
PRODHProline dehydrogenase 1A mitochondrial protein that catalyses the oxidation of proline and its conversion into P5C in a FAD-dependent mannerUpregulation in both mRNA and protein levels;
overexpression promoted PCa tumour growth and reduced T-cell infiltration in mice
[117]
PYCR1Pyrroline-5-carboxylate reductase 1One of the isoforms of the pyrroline-5-carboxylate reductase, which is involved in proline biosynthesisPYCR1 knockdown suppressed the growth of DU145 and PC-3 cells[118,119]
TryptophanINMTIndolethylamine N-methyltransferaseInvolved in the methylation of indolethylamines, such as tryptamine and serotonin, converting them into N-methylated derivativesLow expression in primary PCa but elevated in CRPC.; INMT knockdown in DU145 cells was inhibitory to cell proliferation[120,121,122]
MultipleAOX1Aldehyde oxidase 1Exhibits a broad substrate specificity and involved in cell redox homeostasis by regulating the production of reactive oxygen speciesHypermethylated and downregulated;
overexpression inhibited the proliferation and invasion of PC-3 cells
[123,124]
ASPAAspartoacylaseCrucial to the breakdown of N-acetylaspartate into aspartate and acetate Inhibited the phosphorylation of LYN and suppressed the proliferation, migration and invasion of PC-3 cells[125]
CBSCystathionine beta-synthaseThe rate-limiting enzyme in the first step of the transsulfuration pathway, catalysing the conversion of homocysteine into cystathionine; SAM is required for the allosteric activation of its homotetramerElevated in the early stages but drops during tumour metastasis[126]
GNMTGlycine N-methyltransferaseCatalyses the transfer of a methyl group from SAM to glycine, producing S-adenosylhomocysteine and sarcosineRegulated in an AR-dependent manner and contributed to the survival of PCa cells[127,128,129]
MAOBMonoamine oxidase BLocated at the mitochondrial outer membrane and involved in the breakdown of monoamines, including neurotransmitters like dopamine and serotoninDecreased expression could enhance the proliferation of PC-3 cells and was associated with a poor prognosis in PCa patients[130,131]
SMSSpermine synthaseCatalyses the production of spermine from spermidine and decarboxylated SAMSensitive to androgen exposure [132,133,134]
a: ↑ indicates that the gene is upregulated in PCa; b: ↓ indicates that the gene is downregulated in PCa.

3. Signalling Pathways Affected by an Altered AAM in PCa

3.1. mTOR

Amino acids are the cornerstone of protein synthesis. Distinct amino acids utilise a series of signal transduction mechanisms to modulate the mRNA translation machinery. In mammalian cells, mTOR serves as a central hub for sensing environmental stimuli, including amino acids, to promote protein synthesis and modulate anabolic pathways, thus governing cell growth and proliferation [135]. mTOR is a serine/threonine protein kinase that acts as the catalytic subunit of two distinct protein complexes, mTORC1 and 2. Amino acids can activate mTORC1 via RAG GTPase-dependent and -independent pathways. RAGs facilitate the recruitment of mTORC1 to the lysosomal surface, where it can be activated by its upstream activator Rheb-GTP [136]. Certain amino acids, such as leucine and arginine, act as positive regulators of mTORC1 by evoking the activation of RAGs [137,138]. Cells can also directly sense changes in amino acid levels through specific intracellular sensors, including the leucine sensors Sestrin2 [139], SAR1B [140] and LARS [141] and the arginine sensors CASTOR1 [137] and SLC38A9 [142]. It is noteworthy that many amino acid transporters are multi-functional; they can serve as receptors for sensing amino acid signals, as well as becoming the gateways for amino acid entry through the plasma membrane. For example, leucine is transported into cells via the L-type amino acid transporter (LAT) family. The inhibition of LAT proteins using the leucine analogue BCH reduced mTORC1 activation and suppressed the growth of PCa cells (LNCaP, PC-3 and DU145) [143,144]. Interestingly, the primary LAT protein used by PCa cells to intake leucine can alter according to the disease progression. In localised prostate tumours, PCa cells predominantly rely on LAT3 (SLC43A1) for leucine transport. However, as the cancer progresses to CRPC, the LAT3 expression decreases, whereas LAT1 (SLC7A5) expression increases and becomes the main channel for leucine uptake [144,145]. Supporting this notion, Wang et al. reported that knocking down LAT1, but not LAT3, in androgen-insensitive PC3 cells significantly inhibited mTORC1 activation [143]. Consistent with this notion, the LAT1-specific inhibitor JPH203 also showed potential as an effective treatment for CRPC [146,147].
Glutamine is an amino acid that governs mTORC1 activity via a RAG-independent route, featuring a distinctive and intricate regulatory mechanism. Increased glutamine dependence is commonly observed during the progression of PCa [7], and elevated glutamine levels have been shown to increase the mTORC1 activity in C4-2 cells [148]. The primary transporter of glutamine in PCa cells is ASCT2 (SLC1A5). Inhibition of ASCT2 using its competitive inhibitor BenSer and GPNA has been shown to effectively block the phosphorylation of mTORC1 downstream targets in PC-3 cells; however, this effect was not observed in LNCaP cells [149]. ATP is a crucial energy source for mTOR activation [150], and AMPK (adenosine monophosphate-activated protein kinase) is the principal energy sensor in cells and a negative regulator of mTORC1 [151]. Glutamine can serve as an energy source for increasing intracellular ATP levels and thus indirectly activate mTORC1 by inhibiting AMPK in HMVP2 (murine PCa) cells [152]. In summary, distinct amino acid signalling cues can stimulate mTORC1 through different mechanisms to control protein synthesis and cell fate. Although mTOR inhibitors have been ineffective against PCa in clinical trials so far due to high toxicity and the activation of feedback mechanisms [153], many other amino acid–mTORC1 signalling pathway components may still be suitable therapeutic targets for anti-PCa treatment. For example, Hsueh et al. found that a lack of arginine also inhibited mTOR signalling in PCa cells [154]. Zhao et al. revealed the important role of VWCE in the mTOR response to amino acid starvation in PC-3 cells [155]. For a greater understanding of the signalling process, there is certainly a fertile research area for future studies to explore.

3.2. GCN2

GCN2 is a serine/threonine protein kinase in eukaryotic cells that plays a pivotal role in amino acid sensing and stress responses. Unlike mTORC1, which relies on specific amino acid sensors, GCN2 responds to amino acid deficiency by binding to uncharged tRNAs, and therefore its activation is not constrained by a specific type of amino acid [156], although recent studies have also suggested that GCN2 can be activated in a manner independent of deaminated tRNAs [157]. The activating mechanisms of mTORC1 and GCN2 are illustrated in Figure 2. Once activated, GCN2 phosphorylates eIF2α, leading to global inhibition of protein synthesis while also promoting the translation of specific genes, such as the transcription factor ATF4, which further assists the cells in adapting to amino acid scarcity. Increased expression and phosphorylation levels of GCN2 have been observed in various cancer tissues, including those from colon, lung and breast cancer [158] and PCa [159]. The GCN2-eIF2α-ATF4 signalling axis was found to support cancer cell growth and proliferation by promoting the expression of amino acid transporters and activating autophagy [160]. Amino acid deprivation and uncharged tRNAs were able to activate GCN2 in LNCaP cells, and GCN2 deletion or inhibition reduced PCa cell proliferation in vitro and in vivo [161]. GCN1 (general amino acid control non-depressible 1), as an upstream activator of GCN2, also plays an important role in initiating downstream signalling cascades in response to cellular stress. Furnish et al. noted that MIRO2 engaged in GCN2 sensing of amino acid deficiency by interacting with GCN1 in PCa cells [159], demonstrating MIRO2 as a potential target for GCN2 inhibition. It is noteworthy that after the treatment of PCa cell lines, such as LNCaP, PC3 and 22Rv1, with GCN2iB (a specific competitive inhibitor of GCN2), the growth of these cells was impeded, and a series of genes engaged in AAM were downregulated at both the transcription and translation levels, such as ASNS (induced by ATF4) and a range of SLC gene family members, including SLC7A11 (encoding xCT), SLC7A5 (encoding LAT1) and SLC3A2 (encoding 4F2) [161]. Thus, PCa cells utilise AR- and ATF4-mediated transcriptional pathways to modulate the expression levels of amino acid transporters to sustain a sufficient intracellular amino acid supply. In summary, mTORC1 and GCN2 are two signalling sensors of amino acid availability for controlling protein synthesis, providing the building blocks for PCa cell growth and proliferation. Given the issues with mTOR-inhibitor-related PCa clinical trials, it would be intriguing to consider GCN2 as an alternative anti-PCa treatment target in future clinical studies.

4. Concluding Remarks

AAM is a core component of cellular metabolism, participating in various physiological processes, from protein synthesis to energy production, and is closely linked to maintaining cellular homeostasis and normal cell function. The universality and significance of metabolic reprogramming in cancer cells have increasingly been recognised; thus, focusing on abnormal changes in AAM holds promise for providing new perspectives and potential targets for cancer diagnosis and treatment. In this review, we discussed how the AAM landscape is altered in PCa. Metabolic patterns of certain amino acids such as glutamine, leucine, arginine, methionine and serine are remodelled during the progression of PCa, providing essential nutrients and energy for PCa cell growth and survival. We further explored how amino acids leverage the mTORC1 and GCN2 signalling pathways to stimulate mRNA translation, also in the context of PCa.
Based on these findings, AAM pathways hold promise as therapeutic targets for PCa, and related research has provided a crucial theoretical foundation for developing new treatment strategies for PCa. However, the precise role of many genes related to AAM that are abnormally expressed in PCa (AA_DEGs; see Figure 1) still awaits further investigation. Understanding the regulatory mechanisms of these genes could help elucidate the pathological processes of PCa, particularly in its progression to more refractory phenotypes. These genes may serve as potential therapeutic targets for PCa. Table 1 summarises all of the AAM-related genes covered in this review and their impacts on PCa. On a cautionary note, cell and thus AR specificity can easily be ignored when interpreting amino-acid-signalling- and PCa-related data since different PCa cell lines exhibit distinct levels and isoforms of AR and would therefore have different impact on related signalling pathways. Similarly, changes in the PCa microenvironment under different PCa subtypes (e.g., AR-dependent/independent, CRPC, NEPC) may significantly influence the outcomes of treatment strategies targeting AAM pathways. Therefore, we suggest that when it comes to the choice of the experimental models, future studies should consider making conclusions not only based on established PCa cell lines and murine models but rather also relying on more sophisticated PCa patient sample models (e.g., patient-derived tumour explants and patient-derived xenografts) to consolidate their findings. We anticipate that further elucidation of the molecular mechanisms behind the abnormal and tumour-type-specific AAM in PCa patients will achieve more breakthroughs and advancements for PCa treatment.

Author Contributions

The data collection and analysis were performed by P.Y., P.Y., S.C., Z.Z., Y.G. and Y.W. performed the literature search and wrote the first draft of the manuscript. J.X. and W.L. were involved in the conceptualisation of this work and its critical revision. All authors have read and agreed to the published version of the manuscript.

Funding

South China University of Technology’s Double First Class initiative fund, the Flinders Foundation and the Masonic Charities Trust via the Freemasons Centre for Male Health and Wellbeing (to J.X.). No funding numbers are available for aforementioned funds.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

The datasets analysed during the current study are available in The Cancer Genome Atlas (TCGA) repository at https://portal.gdc.cancer.gov/ (accessed on 19 August 2024), Gene Expression Profiling Interactive Analysis (GEPIA) repository at http://gepia.cancer-pku.cn/ (accessed on 22 July 2024) and Chinese Prostate Cancer Genome and Epigenome Atlas (CPGEA) at http://www.cpgea.com (accessed on 27 October 2021, original publication here: https://doi.org/10.1038/s41586-020-2135-x).

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Bray, F.; Laversanne, M.; Sung, H.; Ferlay, J.; Siegel, R.L.; Soerjomataram, I.; Jemal, A. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2024, 74, 229–263. [Google Scholar] [CrossRef] [PubMed]
  2. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer Statistics, 2022. CA Cancer J. Clin. 2022, 72, 7–33. [Google Scholar] [CrossRef] [PubMed]
  3. Rebello, R.J.; Oing, C.; Knudsen, K.E.; Loeb, S.; Johnson, D.C.; Reiter, R.E.; Gillessen, S.; Van Der Kwast, T.; Bristow, R.G. Prostate Cancer. Nat. Rev. Dis. Primer 2021, 7, 9. [Google Scholar] [CrossRef] [PubMed]
  4. Desai, K.; McManus, J.M.; Sharifi, N. Hormonal Therapy for Prostate Cancer. Endocr. Rev. 2021, 42, 354–373. [Google Scholar] [CrossRef]
  5. Wasim, S.; Lee, S.-Y.; Kim, J. Complexities of Prostate Cancer. Int. J. Mol. Sci. 2022, 23, 14257. [Google Scholar] [CrossRef]
  6. Butler, M.; Van Der Meer, L.T.; Van Leeuwen, F.N. Amino Acid Depletion Therapies: Starving Cancer Cells to Death. Trends Endocrinol. Metab. 2021, 32, 367–381. [Google Scholar] [CrossRef]
  7. Bhowmick, N.; Posadas, E.; Ellis, L.; Freedland, S.J.; Vizio, D.D.; Freeman, M.R.; Theodorescu, D.; Figlin, R.; Gong, J. Targeting Glutamine Metabolism in Prostate Cancer. Front. Biosci.-Elite 2023, 15, 2. [Google Scholar] [CrossRef]
  8. Moon, D.; Hauck, J.S.; Jiang, X.; Quang, H.; Xu, L.; Zhang, F.; Gao, X.; Wild, R.; Everitt, J.I.; Macias, E.; et al. Targeting Glutamine Dependence with DRP-104 Inhibits Proliferation and Tumor Growth of Castration-Resistant Prostate Cancer. Prostate 2024, 84, 349–357. [Google Scholar] [CrossRef]
  9. Fu, Y.-M.; Yu, Z.-X.; Li, Y.-Q.; Ge, X.; Sanchez, P.J.; Fu, X.; Meadows, G.G. Specific Amino Acid Dependency Regulates Invasiveness and Viability of Androgen-Independent Prostate Cancer Cells. Nutr. Cancer 2003, 45, 60–73. [Google Scholar] [CrossRef]
  10. Poirson-Bichat, F.; Gonfalone, G.; Bras-Gonçalves, R.A.; Dutrillaux, B.; Poupon, M.F. Growth of Methionine-Dependent Human Prostate Cancer (PC-3) Is Inhibited by Ethionine Combined with Methionine Starvation. Br. J. Cancer 1997, 75, 1605–1612. [Google Scholar] [CrossRef]
  11. Delage, B.; Fennell, D.A.; Nicholson, L.; McNeish, I.; Lemoine, N.R.; Crook, T.; Szlosarek, P.W. Arginine Deprivation and Argininosuccinate Synthetase Expression in the Treatment of Cancer. Int. J. Cancer 2010, 126, 2762–2772. [Google Scholar] [CrossRef]
  12. Zheng, H.; Dong, B.; Ning, J.; Shao, X.; Zhao, L.; Jiang, Q.; Ji, H.; Cai, A.; Xue, W.; Gao, H. NMR-Based Metabolomics Analysis Identifies Discriminatory Metabolic Disturbances in Tissue and Biofluid Samples for Progressive Prostate Cancer. Clin. Chim. Acta 2020, 501, 241–251. [Google Scholar] [CrossRef] [PubMed]
  13. Zhao, B.; Wang, J.; Chen, L.; Wang, H.; Liang, C.-Z.; Huang, J.; Xu, L.-F. The Role of Glutamine Metabolism in Castration-Resistant Prostate Cancer. Asian J. Androl. 2023, 25, 192–197. [Google Scholar] [CrossRef]
  14. Thiruvalluvan, M.; Billet, S.; Bhowmick, N.A. Antagonizing Glutamine Bioavailability Promotes Radiation Sensitivity in Prostate Cancer. Cancers 2022, 14, 2491. [Google Scholar] [CrossRef] [PubMed]
  15. Dereziński, P.; Klupczynska, A.; Sawicki, W.; Pałka, J.A.; Kokot, Z.J. Amino Acid Profiles of Serum and Urine in Search for Prostate Cancer Biomarkers: A Pilot Study. Int. J. Med. Sci. 2017, 14, 1–12. [Google Scholar] [CrossRef] [PubMed]
  16. Lee, B.; Mahmud, I.; Marchica, J.; Dereziński, P.; Qi, F.; Wang, F.; Joshi, P.; Valerio, F.; Rivera, I.; Patel, V.; et al. Integrated RNA and Metabolite Profiling of Urine Liquid Biopsies for Prostate Cancer Biomarker Discovery. Sci. Rep. 2020, 10, 3716. [Google Scholar] [CrossRef]
  17. Costello, L.C.; Franklin, R.B. The Intermediary Metabolism of the Prostate: A Key to Understanding the Pathogenesis and Progression of Prostate Malignancy. Oncology 2000, 59, 269–282. [Google Scholar] [CrossRef]
  18. Ahmad, F.; Cherukuri, M.K.; Choyke, P.L. Metabolic Reprogramming in Prostate Cancer. Br. J. Cancer 2021, 125, 1185–1196. [Google Scholar] [CrossRef]
  19. Costello, L.C.; Franklin, R.B. A Comprehensive Review of the Role of Zinc in Normal Prostate Function and Metabolism and Its Implications in Prostate Cancer. Arch. Biochem. Biophys. 2016, 611, 100–112. [Google Scholar] [CrossRef]
  20. Singh, K.K.; Desouki, M.M.; Franklin, R.B.; Costello, L.C. Mitochondrial Aconitase and Citrate Metabolism in Malignant and Nonmalignant Human Prostate Tissues. Mol. Cancer 2006, 5, 14. [Google Scholar] [CrossRef]
  21. Pereira-Nunes, A.; Simões-Sousa, S.; Pinheiro, C.; Miranda-Gonçalves, V.; Granja, S.; Baltazar, F. Targeting Lactate Production and Efflux in Prostate Cancer. Biochim. Biophys. Acta Mol. Basis Dis. 2020, 1866, 165894. [Google Scholar] [CrossRef] [PubMed]
  22. Cardoso, H.J.; Carvalho, T.M.A.; Fonseca, L.R.S.; Figueira, M.I.; Vaz, C.V.; Socorro, S. Revisiting Prostate Cancer Metabolism: From Metabolites to Disease and Therapy. Med. Res. Rev. 2021, 41, 1499–1538. [Google Scholar] [CrossRef]
  23. Chetta, P.; Sriram, R.; Zadra, G. Lactate as Key Metabolite in Prostate Cancer Progression: What Are the Clinical Implications? Cancers 2023, 15, 3473. [Google Scholar] [CrossRef] [PubMed]
  24. Xu, L.; Yin, Y.; Li, Y.; Chen, X.; Chang, Y.; Zhang, H.; Liu, J.; Beasley, J.; McCaw, P.; Zhang, H.; et al. A Glutaminase Isoform Switch Drives Therapeutic Resistance and Disease Progression of Prostate Cancer. Proc. Natl. Acad. Sci. USA 2021, 118, e2012748118. [Google Scholar] [CrossRef] [PubMed]
  25. Li, T.; Le, A. Glutamine Metabolism in Cancer. In The Heterogeneity of Cancer Metabolism; Le, A., Ed.; Advances in Experimental Medicine and Biology; Springer International Publishing: Cham, Switzerland, 2018; Volume 1063, pp. 13–32. ISBN 978-3-319-77735-1. [Google Scholar]
  26. Shinka, T.; Onodera, D.; Tanaka, T.; Shoji, N.; Miyazaki, T.; Moriuchi, T.; Fukumoto, T. Serotonin Synthesis and Metabolism-Related Molecules in a Human Prostate Cancer Cell Line. Oncol. Lett. 2011, 2, 211–215. [Google Scholar] [CrossRef]
  27. Zang, X.; Jones, C.M.; Long, T.Q.; Monge, M.E.; Zhou, M.; Walker, L.D.; Mezencev, R.; Gray, A.; McDonald, J.F.; Fernández, F.M. Feasibility of Detecting Prostate Cancer by Ultraperformance Liquid Chromatography-Mass Spectrometry Serum Metabolomics. J. Proteome Res. 2014, 13, 3444–3454. [Google Scholar] [CrossRef]
  28. Mandarano, M.; Orecchini, E.; Bellezza, G.; Vannucci, J.; Ludovini, V.; Baglivo, S.; Tofanetti, F.R.; Chiari, R.; Loreti, E.; Puma, F.; et al. Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer. Int. J. Mol. Sci. 2021, 22, 4403. [Google Scholar] [CrossRef]
  29. Tappenden, D.M.; Hwang, H.J.; Yang, L.; Thomas, R.S.; Lapres, J.J. The Aryl-Hydrocarbon Receptor Protein Interaction Network (AHR-PIN) as Identified by Tandem Affinity Purification (TAP) and Mass Spectrometry. J. Toxicol. 2013, 2013, 279829. [Google Scholar] [CrossRef]
  30. Perez-Castro, L.; Garcia, R.; Venkateswaran, N.; Barnes, S. Tryptophan and Its Metabolites in Normal Physiology and Cancer Etiology. FEBS J. 2023, 290, 7–27. [Google Scholar] [CrossRef]
  31. Li, Z.; Ding, B.; Ali, M.R.K.; Zhao, L.; Zang, X.; Lv, Z. Dual Effect of Tryptamine on Prostate Cancer Cell Growth Regulation: A Pilot Study. Int. J. Mol. Sci. 2022, 23, 11087. [Google Scholar] [CrossRef]
  32. Sivanand, S.; Vander Heiden, M.G. Emerging Roles for Branched-Chain Amino Acid Metabolism in Cancer. Cancer Cell 2020, 37, 147–156. [Google Scholar] [CrossRef] [PubMed]
  33. Ananieva, E.A.; Wilkinson, A.C. Branched-Chain Amino Acid Metabolism in Cancer. Curr. Opin. Clin. Nutr. Metab. Care 2018, 21, 64–70. [Google Scholar] [CrossRef] [PubMed]
  34. Aguilar, E.; Marin De Mas, I.; Zodda, E.; Marin, S.; Morrish, F.; Selivanov, V.; Meca-Cortés, Ó.; Delowar, H.; Pons, M.; Izquierdo, I.; et al. Metabolic Reprogramming and Dependencies Associated with Epithelial Cancer Stem Cells Independent of the Epithelial-Mesenchymal Transition Program. Stem Cells 2016, 34, 1163–1176. [Google Scholar] [CrossRef] [PubMed]
  35. Schcolnik-Cabrera, A.; Juárez-López, D. Dual Contribution of the mTOR Pathway and of the Metabolism of Amino Acids in Prostate Cancer. Cell. Oncol. 2022, 45, 831–859. [Google Scholar] [CrossRef]
  36. Morris, S.M. Regulation of Enzymes of the Urea Cycle and Arginine Metabolism. Annu. Rev. Nutr. 2002, 22, 87–105. [Google Scholar] [CrossRef]
  37. Matos, A.; Carvalho, M.; Bicho, M.; Ribeiro, R. Arginine and Arginases Modulate Metabolism, Tumor Microenvironment and Prostate Cancer Progression. Nutrients 2021, 13, 4503. [Google Scholar] [CrossRef]
  38. Gannon, P.O.; Godin-Ethier, J.; Hassler, M.; Delvoye, N.; Aversa, M.; Poisson, A.O.; Péant, B.; Alam Fahmy, M.; Saad, F.; Lapointe, R.; et al. Androgen-Regulated Expression of Arginase 1, Arginase 2 and Interleukin-8 in Human Prostate Cancer. PLoS ONE 2010, 5, e12107. [Google Scholar] [CrossRef]
  39. Wang, J.; Torbenson, M.; Wang, Q.; Ro, J.Y.; Becich, M. Expression of Inducible Nitric Oxide Synthase in Paired Neoplastic and Non-Neoplastic Primary Prostate Cell Cultures and Prostatectomy Specimen. Urol. Oncol. Semin. Orig. Investig. 2003, 21, 117–122. [Google Scholar] [CrossRef]
  40. Bronte, V.; Kasic, T.; Gri, G.; Gallana, K.; Borsellino, G.; Marigo, I.; Battistini, L.; Iafrate, M.; Prayer-Galetti, T.; Pagano, F.; et al. Boosting Antitumor Responses of T Lymphocytes Infiltrating Human Prostate Cancers. J. Exp. Med. 2005, 201, 1257–1268. [Google Scholar] [CrossRef]
  41. Changou, C.A.; Chen, Y.-R.; Xing, L.; Yen, Y.; Chuang, F.Y.S.; Cheng, R.H.; Bold, R.J.; Ann, D.K.; Kung, H.-J. Arginine Starvation-Associated Atypical Cellular Death Involves Mitochondrial Dysfunction, Nuclear DNA Leakage, and Chromatin Autophagy. Proc. Natl. Acad. Sci. USA 2014, 111, 14147–14152. [Google Scholar] [CrossRef]
  42. Hsu, S.-C.; Chen, C.-L.; Cheng, M.-L.; Chu, C.-Y.; Changou, C.A.; Yu, Y.-L.; Yeh, S.-D.; Kuo, T.-C.; Kuo, C.-C.; Chuu, C.-P.; et al. Arginine Starvation Elicits Chromatin Leakage and cGAS-STING Activation via Epigenetic Silencing of Metabolic and DNA-Repair Genes. Theranostics 2021, 11, 7527–7545. [Google Scholar] [CrossRef] [PubMed]
  43. Chen, C.-L.; Hsu, S.-C.; Chung, T.-Y.; Chu, C.-Y.; Wang, H.-J.; Hsiao, P.-W.; Yeh, S.-D.; Ann, D.K.; Yen, Y.; Kung, H.-J. Arginine Is an Epigenetic Regulator Targeting TEAD4 to Modulate OXPHOS in Prostate Cancer Cells. Nat. Commun. 2021, 12, 2398. [Google Scholar] [CrossRef] [PubMed]
  44. Cheng, C.-T.; Qi, Y.; Wang, Y.-C.; Chi, K.K.; Chung, Y.; Ouyang, C.; Chen, Y.-R.; Oh, M.E.; Sheng, X.; Tang, Y.; et al. Arginine Starvation Kills Tumor Cells through Aspartate Exhaustion and Mitochondrial Dysfunction. Commun. Biol. 2018, 1, 178. [Google Scholar] [CrossRef] [PubMed]
  45. Mecham, J.O.; Rowitch, D.; Wallace, C.D.; Stern, P.H.; Hoffman, R.M. The Metabolic Defect of Methionine Dependence Occurs Frequently in Human Tumor Cell Lines. Biochem. Biophys. Res. Commun. 1983, 117, 429–434. [Google Scholar] [CrossRef]
  46. Chaturvedi, S.; Hoffman, R.M.; Bertino, J.R. Exploiting Methionine Restriction for Cancer Treatment. Biochem. Pharmacol. 2018, 154, 170–173. [Google Scholar] [CrossRef]
  47. Lu, S.; Epner, D.E. Molecular Mechanisms of Cell Cycle Block by Methionine Restriction in Human Prostate Cancer Cells. Nutr. Cancer 2000, 38, 123–130. [Google Scholar] [CrossRef]
  48. Liu, X.; Fu, Y.-M.; Meadows, G.G. Differential Effects of Specific Amino Acid Restriction on Glucose Metabolism, Reduction/Oxidation Status and Mitochondrial Damage in DU145 and PC3 Prostate Cancer Cells. Oncol. Lett. 2011, 2, 349–355. [Google Scholar] [CrossRef]
  49. Fu, Y.; Zhang, H.; Ding, M.; Li, Y.; Fu, X.; Yu, Z.; Meadows, G.G. Selective Amino Acid Restriction Targets Mitochondria to Induce Apoptosis of Androgen-independent Prostate Cancer Cells. J. Cell. Physiol. 2006, 209, 522–534. [Google Scholar] [CrossRef]
  50. Fu, Y.-M.; Yu, Z.-X.; Lin, H.; Fu, X.; Meadows, G.G. Selective Amino Acid Restriction Differentially Affects the Motility and Directionality of DU145 and PC3 Prostate Cancer Cells. J. Cell. Physiol. 2008, 217, 184–193. [Google Scholar] [CrossRef]
  51. Han, Q.; Hoffman, R.M. Lowering and Stabilizing PSA Levels in Advanced-Prostate Cancer Patients With Oral Methioninase. Anticancer Res. 2021, 41, 1921. [Google Scholar] [CrossRef]
  52. Han, Q.; Tan, Y.; Hoffman, R.M. Oral Dosing of Recombinant Methioninase Is Associated With a 70% Drop in PSA in a Patient With Bone-Metastatic Prostate Cancer and 50% Reduction in Circulating Methionine in a High-Stage Ovarian Cancer Patient. Anticancer Res. 2020, 40, 2813. [Google Scholar] [CrossRef] [PubMed]
  53. Ren, S.; Shao, Y.; Zhao, X.; Hong, C.S.; Wang, F.; Lu, X.; Li, J.; Ye, G.; Yan, M.; Zhuang, Z.; et al. Integration of Metabolomics and Transcriptomics Reveals Major Metabolic Pathways and Potential Biomarker Involved in Prostate Cancer. Mol. Cell. Proteom. 2016, 15, 154–163. [Google Scholar] [CrossRef] [PubMed]
  54. Tomasi, M.L.; Cossu, C.; Spissu, Y.; Floris, A.; Ryoo, M.; Iglesias-Ara, A.; Wang, Q.; Pandol, S.J.; Bhowmick, N.A.; Seki, E.; et al. S-Adenosylmethionine and Methylthioadenosine Inhibit Cancer Metastasis by Targeting microRNA 34a/b-Methionine Adenosyltransferase 2A/2B Axis. Oncotarget 2017, 8, 78851–78869. [Google Scholar] [CrossRef] [PubMed]
  55. Maldonado, L.Y.; Arsene, D.; Mato, J.M.; Lu, S.C. Methionine Adenosyltransferases in Cancers: Mechanisms of Dysregulation and Implications for Therapy. Exp. Biol. Med. 2018, 243, 107–117. [Google Scholar] [CrossRef]
  56. Cacciatore, A.; Shinde, D.; Musumeci, C.; Sandrini, G.; Guarrera, L.; Albino, D.; Civenni, G.; Storelli, E.; Mosole, S.; Federici, E.; et al. Epigenome-Wide Impact of MAT2A Sustains the Androgen-Indifferent State and Confers Synthetic Vulnerability in ERG Fusion-Positive Prostate Cancer. Nat. Commun. 2024, 15, 6672. [Google Scholar] [CrossRef]
  57. Schmidt, T.; Leha, A.; Salinas-Riester, G. Treatment of Prostate Cancer Cells with S-Adenosylmethionine Leads to Genome-Wide Alterations in Transcription Profiles. Gene 2016, 595, 161–167. [Google Scholar] [CrossRef]
  58. Schmidt, T. S-Adenosylmethionine Affects ERK1/2 and STAT3 Pathway in Androgen-Independent Prostate Cancer Cells. Mol. Biol. Rep. 2022, 49, 4805–4817. [Google Scholar] [CrossRef]
  59. Shukeir, N.; Pakneshan, P.; Chen, G.; Szyf, M.; Rabbani, S.A. Alteration of the Methylation Status of Tumor-Promoting Genes Decreases Prostate Cancer Cell Invasiveness and Tumorigenesis In Vitro and In Vivo. Cancer Res. 2006, 66, 9202–9210. [Google Scholar] [CrossRef]
  60. Mathes, A.; Duman, M.B.; Neumann, A.; Dobreva, G.; Schmidt, T. S-Adenosylmethionine Treatment Affects Histone Methylation in Prostate Cancer Cells. Gene 2024, 893, 147915. [Google Scholar] [CrossRef]
  61. Branco, A.C.C.C.; Yoshikawa, F.S.Y.; Pietrobon, A.J.; Sato, M.N. Role of Histamine in Modulating the Immune Response and Inflammation. Mediat. Inflamm. 2018, 2018, 9524075. [Google Scholar] [CrossRef]
  62. Matsushita, M.; Fujita, K.; Hatano, K.; Hayashi, T.; Kayama, H.; Motooka, D.; Hase, H.; Yamamoto, A.; Uemura, T.; Yamamichi, G.; et al. High-Fat Diet Promotes Prostate Cancer Growth through Histamine Signaling. Int. J. Cancer 2022, 151, 623–636. [Google Scholar] [CrossRef] [PubMed]
  63. Labuschagne, C.F.; van den Broek, N.J.F.; Mackay, G.M.; Vousden, K.H.; Maddocks, O.D.K. Serine, but Not Glycine, Supports One-Carbon Metabolism and Proliferation of Cancer Cells. Cell Rep. 2014, 7, 1248–1258. [Google Scholar] [CrossRef]
  64. Holeček, M. Serine Metabolism in Health and Disease and as a Conditionally Essential Amino Acid. Nutrients 2022, 14, 1987. [Google Scholar] [CrossRef]
  65. Wang, W.; He, Z.; Kong, Y.; Liu, Z.; Gong, L. GC-MS-Based Metabolomics Reveals New Biomarkers to Assist the Differentiation of Prostate Cancer and Benign Prostatic Hyperplasia. Clin. Chim. Acta 2021, 519, 10–17. [Google Scholar] [CrossRef]
  66. Falegan, O.S.; Jarvi, K.; Vogel, H.J.; Hyndman, M.E. Seminal Plasma Metabolomics Reveals Lysine and Serine Dysregulation as Unique Features Distinguishing between Prostate Cancer Tumors of Gleason Grades 6 and 7. Prostate 2021, 81, 713–720. [Google Scholar] [CrossRef] [PubMed]
  67. Saruta, M.; Takahara, K.; Yoshizawa, A.; Niimi, A.; Takeuchi, T.; Nukaya, T.; Takenaka, M.; Zennami, K.; Ichino, M.; Sasaki, H.; et al. Alanine-Serine-Cysteine Transporter 2 Inhibition Suppresses Prostate Cancer Cell Growth In Vitro. J. Clin. Med. 2022, 11, 5466. [Google Scholar] [CrossRef]
  68. Buqué, A.; Galluzzi, L.; Montrose, D.C. Targeting Serine in Cancer: Is Two Better Than One? Trends Cancer 2021, 7, 668–670. [Google Scholar] [CrossRef] [PubMed]
  69. Reina-Campos, M.; Linares, J.F.; Duran, A.; Cordes, T.; L’Hermitte, A.; Badur, M.G.; Bhangoo, M.S.; Thorson, P.K.; Richards, A.; Rooslid, T.; et al. Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer. Cancer Cell 2019, 35, 385–400.e9. [Google Scholar] [CrossRef]
  70. Sun, W.; Zhao, E.; Cui, H. Target Enzymes in Serine-glycine-one-carbon Metabolic Pathway for Cancer Therapy. Int. J. Cancer 2023, 152, 2446–2463. [Google Scholar] [CrossRef]
  71. Li, A.M.; Ye, J. Reprogramming of Serine, Glycine and One-Carbon Metabolism in Cancer. Biochim. Biophys. Acta Mol. Basis Dis. 2020, 1866, 165841. [Google Scholar] [CrossRef]
  72. Chandrika, M.; Chua, P.J.; Muniasamy, U.; Huang, R.Y.J.; Thike, A.A.; Ng, C.T.; Tan, P.H.; Yip, G.W.; Bay, B.H. Prognostic Significance of Phosphoglycerate Dehydrogenase in Breast Cancer. Breast Cancer Res. Treat. 2021, 186, 655–665. [Google Scholar] [CrossRef] [PubMed]
  73. Shen, L.; Zhang, J.; Zheng, Z.; Yang, F.; Liu, S.; Wu, Y.; Chen, Y.; Xu, T.; Mao, S.; Yan, Y.; et al. PHGDH Inhibits Ferroptosis and Promotes Malignant Progression by Upregulating SLC7A11 in Bladder Cancer. Int. J. Biol. Sci. 2022, 18, 5459–5474. [Google Scholar] [CrossRef] [PubMed]
  74. Rathore, R.; Schutt, C.R.; Van Tine, B.A. PHGDH as a Mechanism for Resistance in Metabolically-Driven Cancers. Cancer Drug Resist. 2020, 3, 762–774. [Google Scholar] [CrossRef]
  75. Wang, J.; Zeng, L.; Wu, N.; Liang, Y.; Jin, J.; Fan, M.; Lai, X.; Chen, Z.-S.; Pan, Y.; Zeng, F.; et al. Inhibition of Phosphoglycerate Dehydrogenase Induces Ferroptosis and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells. Drug Resist. Updat. 2023, 70, 100985. [Google Scholar] [CrossRef] [PubMed]
  76. Lee, G.Y.; Haverty, P.M.; Li, L.; Kljavin, N.M.; Bourgon, R.; Lee, J.; Stern, H.; Modrusan, Z.; Seshagiri, S.; Zhang, Z.; et al. Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes. Cancer Res. 2014, 74, 3114–3126. [Google Scholar] [CrossRef]
  77. Zeng, Y.; Zhang, J.; Xu, M.; Chen, F.; Zi, R.; Yue, J.; Zhang, Y.; Chen, N.; Chin, Y.E. Roles of Mitochondrial Serine Hydroxymethyltransferase 2 (SHMT2) in Human Carcinogenesis. J. Cancer 2021, 12, 5888–5894. [Google Scholar] [CrossRef]
  78. Chen, L.; Liu, H.; Ji, Y.; Ma, Z.; Shen, K.; Shangguan, X.; Qian, H.; Zhao, Y.; Pan, C.-W.; Xue, W. Downregulation of SHMT2 Promotes the Prostate Cancer Proliferation and Metastasis by Inducing Epithelial-Mesenchymal Transition. Exp. Cell Res. 2022, 415, 113138. [Google Scholar] [CrossRef]
  79. Marrocco, I.; Altieri, F.; Rubini, E.; Paglia, G.; Chichiarelli, S.; Giamogante, F.; Macone, A.; Perugia, G.; Magliocca, F.M.; Gurtner, A.; et al. Shmt2: A Stat3 Signaling New Player in Prostate Cancer Energy Metabolism. Cells 2019, 8, 1048. [Google Scholar] [CrossRef]
  80. Jain, M.; Nilsson, R.; Sharma, S.; Madhusudhan, N.; Kitami, T.; Souza, A.L.; Kafri, R.; Kirschner, M.W.; Clish, C.B.; Mootha, V.K. Metabolite Profiling Identifies a Key Role for Glycine in Rapid Cancer Cell Proliferation. Science 2012, 336, 1040–1044. [Google Scholar] [CrossRef]
  81. Kumar, D.; Gupta, A.; Mandhani, A.; Sankhwar, S.N. NMR Spectroscopy of Filtered Serum of Prostate Cancer: A New Frontier in Metabolomics: Metabolomics of Prostate Cancer. Prostate 2016, 76, 1106–1119. [Google Scholar] [CrossRef]
  82. Kumar, D.; Gupta, A.; Mandhani, A.; Sankhwar, S.N. Metabolomics-Derived Prostate Cancer Biomarkers: Fact or Fiction? J. Proteome Res. 2015, 14, 1455–1464. [Google Scholar] [CrossRef] [PubMed]
  83. Pérez-Rambla, C.; Puchades-Carrasco, L.; García-Flores, M.; Rubio-Briones, J.; López-Guerrero, J.A.; Pineda-Lucena, A. Non-Invasive Urinary Metabolomic Profiling Discriminates Prostate Cancer from Benign Prostatic Hyperplasia. Metabolomics 2017, 13, 52. [Google Scholar] [CrossRef] [PubMed]
  84. Yang, B.; Zhang, C.; Cheng, S.; Li, G.; Griebel, J.; Neuhaus, J. Novel Metabolic Signatures of Prostate Cancer Revealed by 1H-NMR Metabolomics of Urine. Diagnostics 2021, 11, 149. [Google Scholar] [CrossRef] [PubMed]
  85. Gómez-Cebrián, N.; García-Flores, M.; Rubio-Briones, J.; López-Guerrero, J.A.; Pineda-Lucena, A.; Puchades-Carrasco, L. Targeted Metabolomics Analyses Reveal Specific Metabolic Alterations in High-Grade Prostate Cancer Patients. J. Proteome Res. 2020, 19, 4082–4092. [Google Scholar] [CrossRef] [PubMed]
  86. Amelio, I.; Cutruzzolá, F.; Antonov, A.; Agostini, M.; Melino, G. Serine and Glycine Metabolism in Cancer. Trends Biochem. Sci. 2014, 39, 191–198. [Google Scholar] [CrossRef]
  87. Liu, R.; Zeng, L.-W.; Gong, R.; Yuan, F.; Shu, H.-B.; Li, S. mTORC1 Activity Regulates Post-Translational Modifications of Glycine Decarboxylase to Modulate Glycine Metabolism and Tumorigenesis. Nat. Commun. 2021, 12, 4227. [Google Scholar] [CrossRef]
  88. Yu, H.; Hu, X.; Zhang, Y.; Wang, J.; Ni, Z.; Wang, Y.; Zhu, H. GLDC Promotes Colorectal Cancer Metastasis through Epithelial–Mesenchymal Transition Mediated by Hippo Signaling Pathway. Med. Oncol. 2023, 40, 293. [Google Scholar] [CrossRef]
  89. Meiser, J.; Vazquez, A. Give It or Take It: The Flux of One-carbon in Cancer Cells. FEBS J. 2016, 283, 3695–3704. [Google Scholar] [CrossRef]
  90. Mukha, D.; Fokra, M.; Feldman, A.; Sarvin, B.; Sarvin, N.; Nevo-Dinur, K.; Besser, E.; Hallo, E.; Aizenshtein, E.; Schug, Z.T.; et al. Glycine Decarboxylase Maintains Mitochondrial Protein Lipoylation to Support Tumor Growth. Cell Metab. 2022, 34, 775–782.e9. [Google Scholar] [CrossRef]
  91. Kikuchi, G.; Motokawa, Y.; Yoshida, T.; Hiraga, K. Glycine Cleavage System: Reaction Mechanism, Physiological Significance, and Hyperglycinemia. Proc. Jpn. Acad. Ser. B 2008, 84, 246–263. [Google Scholar] [CrossRef]
  92. Woo, C.C.; Kaur, K.; Chan, W.X.; Teo, X.Q.; Lee, T.H.P. Inhibiting Glycine Decarboxylase Suppresses Pyruvate-to-Lactate Metabolism in Lung Cancer Cells. Front. Oncol. 2018, 8, 196. [Google Scholar] [CrossRef] [PubMed]
  93. Zhang, W.C.; Shyh-Chang, N.; Yang, H.; Rai, A.; Umashankar, S.; Ma, S.; Soh, B.S.; Sun, L.L.; Tai, B.C.; Nga, M.E.; et al. Glycine Decarboxylase Activity Drives Non-Small Cell Lung Cancer Tumor-Initiating Cells and Tumorigenesis. Cell 2012, 148, 259–272. [Google Scholar] [CrossRef]
  94. Xie, H.; Yan, T.; Lu, X.; Du, Y.; Xu, S.; Kong, Y.; Yu, L.; Sun, J.; Zhou, L.; Ma, J. GLDC Mitigated by miR-30e Regulates Cell Proliferation and Tumor Immune Infiltration in TNBC. Front. Immunol. 2022, 13, 1033367. [Google Scholar] [CrossRef] [PubMed]
  95. Chen, M.; Xiao, Z.-Y.; Huang, Z.-P.; Xue, K.-Y.; Xia, H.; Zhou, J.-W.; Liao, D.-Y.; Liang, Z.-J.; Xie, X.; Wei, Q.-Z.; et al. Glycine Decarboxylase (GLDC) Plays a Crucial Role in Regulating Energy Metabolism, Invasion, Metastasis and Immune Escape for Prostate Cancer. Int. J. Biol. Sci. 2023, 19, 4726–4743. [Google Scholar] [CrossRef] [PubMed]
  96. Yu, Y.C.; Han, J.M.; Kim, S. Aminoacyl-tRNA Synthetases and Amino Acid Signaling. Biochim. Biophys. Acta BBA Mol. Cell Res. 2021, 1868, 118889. [Google Scholar] [CrossRef]
  97. Zhou, Z.; Sun, B.; Nie, A.; Yu, D.; Bian, M. Roles of Aminoacyl-tRNA Synthetases in Cancer. Front. Cell Dev. Biol. 2020, 8, 599765. [Google Scholar] [CrossRef]
  98. Kwon, N.H.; Fox, P.L.; Kim, S. Aminoacyl-tRNA Synthetases as Therapeutic Targets. Nat. Rev. Drug Discov. 2019, 18, 629–650. [Google Scholar] [CrossRef]
  99. Vellaichamy, A.; Sreekumar, A.; Strahler, J.R.; Rajendiran, T.; Yu, J.; Varambally, S.; Li, Y.; Omenn, G.S.; Chinnaiyan, A.M.; Nesvizhskii, A.I. Proteomic Interrogation of Androgen Action in Prostate Cancer Cells Reveals Roles of Aminoacyl tRNA Synthetases. PLoS ONE 2009, 4, e7075. [Google Scholar] [CrossRef]
  100. Sangha, A.K.; Kantidakis, T. The Aminoacyl-tRNA Synthetase and tRNA Expression Levels Are Deregulated in Cancer and Correlate Independently with Patient Survival. Curr. Issues Mol. Biol. 2022, 44, 3001–3019. [Google Scholar] [CrossRef]
  101. Khosh Kish, E.; Gamallat, Y.; Choudhry, M.; Ghosh, S.; Seyedi, S.; Bismar, T.A. Glycyl-tRNA Synthetase (GARS) Expression Is Associated with Prostate Cancer Progression and Its Inhibition Decreases Migration, and Invasion In Vitro. Int. J. Mol. Sci. 2023, 24, 4260. [Google Scholar] [CrossRef]
  102. Nie, J.; Liu, T.; Mao, T.; Yang, H.; Deng, W.; Liu, X.; Fu, B. Transcriptome Sequencing and Single-Cell Sequencing Analysis Identify GARS1 as a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancers, Including Bladder Cancer. Front. Immunol. 2023, 14, 1169588. [Google Scholar] [CrossRef] [PubMed]
  103. Tang, Z.; Li, C.; Kang, B.; Gao, G.; Li, C.; Zhang, Z. GEPIA: A Web Server for Cancer and Normal Gene Expression Profiling and Interactive Analyses. Nucleic Acids Res. 2017, 45, W98–W102. [Google Scholar] [CrossRef] [PubMed]
  104. Li, J.; Xu, C.; Lee, H.J.; Ren, S.; Zi, X.; Zhang, Z.; Wang, H.; Yu, Y.; Yang, C.; Gao, X.; et al. A Genomic and Epigenomic Atlas of Prostate Cancer in Asian Populations. Nature 2020, 580, 93–99. [Google Scholar] [CrossRef] [PubMed]
  105. Cancer Genome Atlas Research Network. The Molecular Taxonomy of Primary Prostate Cancer. Cell 2015, 163, 1011–1025. [Google Scholar] [CrossRef]
  106. Huang, Y.; Yang, G.; Yao, X.; Fang, Y.; Lin, Q.; Zhou, M.; Yang, Y.; Meng, Q.; Zhang, Q.; Wang, S. Proteomic Profiling of Prostate Cancer Reveals Molecular Signatures under Antiandrogen Treatment. Clin. Proteom. 2024, 21, 44. [Google Scholar] [CrossRef]
  107. Jeong, S.-H.; Kwak, C. Prostate-Specific Membrane Antigen-Mediated Theragnostics in Prostate Cancer. Investig. Clin. Urol. 2021, 62, 497–499. [Google Scholar] [CrossRef]
  108. Stamatakos, P.V.; Fragkoulis, C.; Leventi, A.; Gklinos, K.; Kontolatis, N.; Papatsoris, A.; Dellis, A. PSMA-Based Therapeutics for Prostate Cancer. Expert. Opin. Pharmacother. 2024, 25, 1405–1419. [Google Scholar] [CrossRef]
  109. Marques, R.B.; Dits, N.F.; Erkens-Schulze, S.; van Ijcken, W.F.J.; van Weerden, W.M.; Jenster, G. Modulation of Androgen Receptor Signaling in Hormonal Therapy-Resistant Prostate Cancer Cell Lines. PLoS ONE 2011, 6, e23144. [Google Scholar] [CrossRef]
  110. He, J.; Mao, Y.; Huang, W.; Li, M.; Zhang, H.; Qing, Y.; Lu, S.; Xiao, H.; Li, K. Methylcrotonoyl-CoA Carboxylase 2 Promotes Proliferation, Migration and Invasion and Inhibits Apoptosis of Prostate Cancer Cells Through Regulating GLUD1-P38 MAPK Signaling Pathway. OncoTargets Ther. 2020, 13, 7317–7327. [Google Scholar] [CrossRef]
  111. Park, S.H.; Fong, K.-W.; Mong, E.; Martin, M.C.; Schiltz, G.E.; Yu, J. Going beyond Polycomb: EZH2 Functions in Prostate Cancer. Oncogene 2021, 40, 5788–5798. [Google Scholar] [CrossRef]
  112. Kaur, P.; Shankar, E.; Gupta, S. EZH2-Mediated Development of Therapeutic Resistance in Cancer. Cancer Lett. 2024, 586, 216706. [Google Scholar] [CrossRef] [PubMed]
  113. Xu, K.; Wu, Z.J.; Groner, A.C.; He, H.H.; Cai, C.; Lis, R.T.; Wu, X.; Stack, E.C.; Loda, M.; Liu, T.; et al. EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent. Science 2012, 338, 1465–1469. [Google Scholar] [CrossRef] [PubMed]
  114. Zhang, Z.; Wang, X.; Kim, M.; He, D.; Wang, C.; Fong, K.W.; Liu, X. Downregulation of EZH2 Inhibits Epithelial-Mesenchymal Transition in Enzalutamide-Resistant Prostate Cancer. Prostate 2023, 83, 1458–1469. [Google Scholar] [CrossRef] [PubMed]
  115. Queisser, A.; Hagedorn, S.; Wang, H.; Schaefer, T.; Konantz, M.; Alavi, S.; Deng, M.; Vogel, W.; von Mässenhausen, A.; Kristiansen, G.; et al. Ecotropic Viral Integration Site 1, a Novel Oncogene in Prostate Cancer. Oncogene 2017, 36, 1573–1584. [Google Scholar] [CrossRef]
  116. Jariwala, U.; Prescott, J.; Jia, L.; Barski, A.; Pregizer, S.; Cogan, J.P.; Arasheben, A.; Tilley, W.D.; Scher, H.I.; Gerald, W.L.; et al. Identification of Novel Androgen Receptor Target Genes in Prostate Cancer. Mol. Cancer 2007, 6, 39. [Google Scholar] [CrossRef]
  117. Yan, Y.; Chang, L.; Tian, H.; Wang, L.; Zhang, Y.; Yang, T.; Li, G.; Hu, W.; Shah, K.; Chen, G.; et al. 1-Pyrroline-5-Carboxylate Released by Prostate Cancer Cell Inhibit T Cell Proliferation and Function by Targeting SHP1/Cytochrome c Oxidoreductase/ROS Axis. J. Immunother. Cancer 2018, 6, 148. [Google Scholar] [CrossRef]
  118. Xu, H.; He, Y.; Lin, L.; Li, M.; Zhou, Z.; Yang, Y. MiR-1207-5p Targets PYCR1 to Inhibit the Progression of Prostate Cancer. Biochem. Biophys. Res. Commun. 2021, 575, 56–64. [Google Scholar] [CrossRef]
  119. Zeng, T.; Zhu, L.; Liao, M.; Zhuo, W.; Yang, S.; Wu, W.; Wang, D. Knockdown of PYCR1 Inhibits Cell Proliferation and Colony Formation via Cell Cycle Arrest and Apoptosis in Prostate Cancer. Med. Oncol. 2017, 34, 27. [Google Scholar] [CrossRef]
  120. Jianfeng, W.; Yutao, W.; Jianbin, B. Indolethylamine-N-Methyltransferase Inhibits Proliferation and Promotes Apoptosis of Human Prostate Cancer Cells: A Mechanistic Exploration. Front. Cell Dev. Biol. 2022, 10, 805402. [Google Scholar] [CrossRef]
  121. Zhong, S.; Jeong, J.-H.; Huang, C.; Chen, X.; Dickinson, S.I.; Dhillon, J.; Yang, L.; Luo, J.-L. Targeting INMT and Interrupting Its Methylation Pathway for the Treatment of Castration Resistant Prostate Cancer. J. Exp. Clin. Cancer Res. 2021, 40, 307. [Google Scholar] [CrossRef]
  122. Larkin, S.E.T.; Holmes, S.; Cree, I.A.; Walker, T.; Basketter, V.; Bickers, B.; Harris, S.; Garbis, S.D.; Townsend, P.A.; Aukim-Hastie, C. Identification of Markers of Prostate Cancer Progression Using Candidate Gene Expression. Br. J. Cancer 2012, 106, 157–165. [Google Scholar] [CrossRef] [PubMed]
  123. Li, W.; Middha, M.; Bicak, M.; Sjoberg, D.D.; Vertosick, E.; Dahlin, A.; Häggström, C.; Hallmans, G.; Rönn, A.-C.; Stattin, P.; et al. Genome-Wide Scan Identifies Role for AOX1 in Prostate Cancer Survival. Eur. Urol. 2018, 74, 710–719. [Google Scholar] [CrossRef]
  124. Wu, J.; Wei, Y.; Li, T.; Lin, L.; Yang, Z.; Ye, L. DNA Methylation-Mediated Lowly Expressed AOX1 Promotes Cell Migration and Invasion of Prostate Cancer. Urol. Int. 2023, 107, 517–525. [Google Scholar] [CrossRef]
  125. Weng, H.; Xiong, K.-P.; Wang, W.; Qian, K.-Y.; Yuan, S.; Wang, G.; Yu, F.; Luo, J.; Lu, M.-X.; Yang, Z.-H.; et al. Aspartoacylase Suppresses Prostate Cancer Progression by Blocking LYN Activation. Mil. Med. Res. 2023, 10, 25. [Google Scholar] [CrossRef] [PubMed]
  126. Ascenção, K.; Szabo, C. Emerging Roles of Cystathionine β-Synthase in Various Forms of Cancer. Redox Biol. 2022, 53, 102331. [Google Scholar] [CrossRef] [PubMed]
  127. Zabala-Letona, A.; Arruabarrena-Aristorena, A.; Fernandez-Ruiz, S.; Viera, C.; Carlevaris, O.; Ercilla, A.; Mendizabal, I.; Martin, T.; Macchia, A.; Camacho, L.; et al. PI3K-Regulated Glycine N-Methyltransferase Is Required for the Development of Prostate Cancer. Oncogenesis 2022, 11, 10. [Google Scholar] [CrossRef] [PubMed]
  128. Song, Y.H.; Shiota, M.; Kuroiwa, K.; Naito, S.; Oda, Y. The Important Role of Glycine N-Methyltransferase in the Carcinogenesis and Progression of Prostate Cancer. Mod. Pathol. 2011, 24, 1272–1280. [Google Scholar] [CrossRef]
  129. Ottaviani, S.; Brooke, G.N.; O’Hanlon-Brown, C.; Waxman, J.; Ali, S.; Buluwela, L. Characterisation of the Androgen Regulation of Glycine N-Methyltransferase in Prostate Cancer Cells. J. Mol. Endocrinol. 2013, 51, 301–312. [Google Scholar] [CrossRef]
  130. Pu, T.; Wang, J.; Wei, J.; Zeng, A.; Zhang, J.; Chen, J.; Yin, L.; Li, J.; Lin, T.-P.; Melamed, J.; et al. Stromal-Derived MAOB Promotes Prostate Cancer Growth and Progression. Sci. Adv. 2024, 10, eadi4935. [Google Scholar] [CrossRef]
  131. Huang, H.-C.; Hsieh, Y.-H.; Hsiao, C.-H.; Lin, C.-Y.; Wang, S.-S.; Ho, K.-H.; Chang, L.-C.; Huang, H.-M.; Yang, S.-F.; Chien, M.-H. MAOB Expression Correlates with a Favourable Prognosis in Prostate Cancer, and Its Genetic Variants Are Associated with the Metastasis of the Disease. J. Cell. Mol. Med. 2024, 28, e18229. [Google Scholar] [CrossRef]
  132. Shukla-Dave, A.; Castillo-Martin, M.; Chen, M.; Lobo, J.; Gladoun, N.; Collazo-Lorduy, A.; Khan, F.M.; Ponomarev, V.; Yi, Z.; Zhang, W.; et al. Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling. Am. J. Pathol. 2016, 186, 3131–3145. [Google Scholar] [CrossRef] [PubMed]
  133. DePrimo, S.E.; Diehn, M.; Nelson, J.B.; Reiter, R.E.; Matese, J.; Fero, M.; Tibshirani, R.; Brown, P.O.; Brooks, J.D. Transcriptional Programs Activated by Exposure of Human Prostate Cancer Cells to Androgen. Genome Biol. 2002, 3, research0032.1. [Google Scholar] [CrossRef]
  134. Giskeødegård, G.F.; Bertilsson, H.; Selnæs, K.M.; Wright, A.J.; Bathen, T.F.; Viset, T.; Halgunset, J.; Angelsen, A.; Gribbestad, I.S.; Tessem, M.-B. Spermine and Citrate as Metabolic Biomarkers for Assessing Prostate Cancer Aggressiveness. PLoS ONE 2013, 8, e62375. [Google Scholar] [CrossRef] [PubMed]
  135. Saxton, R.A.; Sabatini, D.M. mTOR Signaling in Growth, Metabolism, and Disease. Cell 2017, 168, 960–976. [Google Scholar] [CrossRef] [PubMed]
  136. Sancak, Y.; Peterson, T.R.; Shaul, Y.D.; Lindquist, R.A.; Thoreen, C.C.; Bar-Peled, L.; Sabatini, D.M. The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1. Science 2008, 320, 1496–1501. [Google Scholar] [CrossRef]
  137. Chantranupong, L.; Scaria, S.M.; Saxton, R.A.; Gygi, M.P.; Shen, K.; Wyant, G.A.; Wang, T.; Harper, J.W.; Gygi, S.P.; Sabatini, D.M. The CASTOR Proteins Are Arginine Sensors for the mTORC1 Pathway. Cell 2016, 165, 153–164. [Google Scholar] [CrossRef]
  138. Jewell, J.L.; Kim, Y.C.; Russell, R.C.; Yu, F.-X.; Park, H.W.; Plouffe, S.W.; Tagliabracci, V.S.; Guan, K.-L. Differential Regulation of mTORC1 by Leucine and Glutamine. Science 2015, 347, 194–198. [Google Scholar] [CrossRef]
  139. Wolfson, R.L.; Chantranupong, L.; Saxton, R.A.; Shen, K.; Scaria, S.M.; Cantor, J.R.; Sabatini, D.M. Sestrin2 Is a Leucine Sensor for the mTORC1 Pathway. Science 2016, 351, 43–48. [Google Scholar] [CrossRef]
  140. Chen, J.; Ou, Y.; Luo, R.; Wang, J.; Wang, D.; Guan, J.; Li, Y.; Xia, P.; Chen, P.R.; Liu, Y. SAR1B Senses Leucine Levels to Regulate mTORC1 Signalling. Nature 2021, 596, 281–284. [Google Scholar] [CrossRef]
  141. Han, J.M.; Jeong, S.J.; Park, M.C.; Kim, G.; Kwon, N.H.; Kim, H.K.; Ha, S.H.; Ryu, S.H.; Kim, S. Leucyl-tRNA Synthetase Is an Intracellular Leucine Sensor for the mTORC1-Signaling Pathway. Cell 2012, 149, 410–424. [Google Scholar] [CrossRef]
  142. Rebsamen, M.; Pochini, L.; Stasyk, T.; De Araújo, M.E.G.; Galluccio, M.; Kandasamy, R.K.; Snijder, B.; Fauster, A.; Rudashevskaya, E.L.; Bruckner, M.; et al. SLC38A9 Is a Component of the Lysosomal Amino Acid Sensing Machinery That Controls mTORC1. Nature 2015, 519, 477–481. [Google Scholar] [CrossRef]
  143. Wang, Q.; Bailey, C.G.; Ng, C.; Tiffen, J.; Thoeng, A.; Minhas, V.; Lehman, M.L.; Hendy, S.C.; Buchanan, G.; Nelson, C.C.; et al. Androgen Receptor and Nutrient Signaling Pathways Coordinate the Demand for Increased Amino Acid Transport during Prostate Cancer Progression. Cancer Res. 2011, 71, 7525–7536. [Google Scholar] [CrossRef] [PubMed]
  144. Otsuki, H.; Kimura, T.; Yamaga, T.; Kosaka, T.; Suehiro, J.; Sakurai, H. Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters. Prostate 2017, 77, 222–233. [Google Scholar] [CrossRef] [PubMed]
  145. Wang, Q.; Tiffen, J.; Bailey, C.G.; Lehman, M.L.; Ritchie, W.; Fazli, L.; Metierre, C.; Feng, Y.; Li, E.; Gleave, M.; et al. Targeting Amino Acid Transport in Metastatic Castration-Resistant Prostate Cancer: Effects on Cell Cycle, Cell Growth, and Tumor Development. JNCI J. Natl. Cancer Inst. 2013, 105, 1463–1473. [Google Scholar] [CrossRef] [PubMed]
  146. Rii, J.; Sakamoto, S.; Mizokami, A.; Xu, M.; Fujimoto, A.; Saito, S.; Koike, H.; Tamura, T.; Arai, T.; Yamada, Y.; et al. L-type Amino Acid Transporter 1 Inhibitor JPH203 Prevents the Growth of Cabazitaxel-resistant Prostate Cancer by Inhibiting Cyclin-dependent Kinase Activity. Cancer Sci. 2024, 115, 937–953. [Google Scholar] [CrossRef]
  147. Saito, S.; Ando, K.; Sakamoto, S.; Xu, M.; Yamada, Y.; Rii, J.; Kanaoka, S.; Wei, J.; Zhao, X.; Pae, S.; et al. The LAT1 Inhibitor JPH203 Suppresses the Growth of Castration-resistant Prostate Cancer through a CD24 -mediated Mechanism. Cancer Sci. 2024, 115, 2461–2472. [Google Scholar] [CrossRef]
  148. Dasgupta, S.; Putluri, N.; Long, W.; Zhang, B.; Wang, J.; Kaushik, A.K.; Arnold, J.M.; Bhowmik, S.K.; Stashi, E.; Brennan, C.A.; et al. Coactivator SRC-2-Dependent Metabolic Reprogramming Mediates Prostate Cancer Survival and Metastasis. J. Clin. Investig. 2015, 125, 1174–1188. [Google Scholar] [CrossRef]
  149. Wang, Q.; Hardie, R.-A.; Hoy, A.J.; van Geldermalsen, M.; Gao, D.; Fazli, L.; Sadowski, M.C.; Balaban, S.; Schreuder, M.; Nagarajah, R.; et al. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. J. Pathol. 2015, 236, 278–289. [Google Scholar] [CrossRef]
  150. Dennis, P.B.; Jaeschke, A.; Saitoh, M.; Fowler, B.; Kozma, S.C.; Thomas, G. Mammalian TOR: A Homeostatic ATP Sensor. Science 2001, 294, 1102–1105. [Google Scholar] [CrossRef]
  151. Xu, J.; Ji, J.; Yan, X.-H. Cross-Talk between AMPK and mTOR in Regulating Energy Balance. Crit. Rev. Food Sci. Nutr. 2012, 52, 373–381. [Google Scholar] [CrossRef]
  152. Lodi, A.; Saha, A.; Lu, X.; Wang, B.; Sentandreu, E.; Collins, M.; Kolonin, M.G.; DiGiovanni, J.; Tiziani, S. Combinatorial Treatment with Natural Compounds in Prostate Cancer Inhibits Prostate Tumor Growth and Leads to Key Modulations of Cancer Cell Metabolism. NPJ Precis. Oncol. 2017, 1, 18. [Google Scholar] [CrossRef] [PubMed]
  153. Xie, J.; Kusnadi, E.P.; Furic, L.; Selth, L.A. Regulation of mRNA Translation by Hormone Receptors in Breast and Prostate Cancer. Cancers 2021, 13, 3254. [Google Scholar] [CrossRef] [PubMed]
  154. Hsueh, E.C.; Knebel, S.M.; Lo, W.-H.; Leung, Y.-C.; Cheng, P.N.-M.; Hsueh, C.-T. Deprivation of Arginine by Recombinant Human Arginase in Prostate Cancer Cells. J. Hematol. Oncol. 2012, 5, 17. [Google Scholar] [CrossRef] [PubMed]
  155. Zhao, T.; Guan, Y.; Xu, C.; Wang, D.; Guan, J.; Liu, Y. VWCE Modulates Amino Acid-Dependent mTOR Signaling and Coordinates with KICSTOR to Recruit GATOR1 to the Lysosomes. Nat. Commun. 2023, 14, 8464. [Google Scholar] [CrossRef]
  156. Gallinetti, J.; Harputlugil, E.; Mitchell, J.R. Amino Acid Sensing in Dietary-Restriction-Mediated Longevity: Roles of Signal-Transducing Kinases GCN2 and TOR. Biochem. J. 2013, 449, 1–10. [Google Scholar] [CrossRef]
  157. Masson, G.R. Towards a Model of GCN2 Activation. Biochem. Soc. Trans. 2019, 47, 1481–1488. [Google Scholar] [CrossRef]
  158. Ye, J.; Kumanova, M.; Hart, L.S.; Sloane, K.; Zhang, H.; De Panis, D.N.; Bobrovnikova-Marjon, E.; Diehl, J.A.; Ron, D.; Koumenis, C. The GCN2-ATF4 Pathway Is Critical for Tumour Cell Survival and Proliferation in Response to Nutrient Deprivation. EMBO J. 2010, 29, 2082–2096. [Google Scholar] [CrossRef]
  159. Furnish, M.; Boulton, D.P.; Genther, V.; Grofova, D.; Ellinwood, M.L.; Romero, L.; Lucia, M.S.; Cramer, S.D.; Caino, M.C. MIRO2 Regulates Prostate Cancer Cell Growth via GCN1-Dependent Stress Signaling. Mol. Cancer Res. 2022, 20, 607–621. [Google Scholar] [CrossRef]
  160. Gold, L.T.; Masson, G.R. GCN2: Roles in Tumour Development and Progression. Biochem. Soc. Trans. 2022, 50, 737–745. [Google Scholar] [CrossRef]
  161. Cordova, R.A.; Misra, J.; Amin, P.H.; Klunk, A.J.; Damayanti, N.P.; Carlson, K.R.; Elmendorf, A.J.; Kim, H.-G.; Mirek, E.T.; Elzey, B.D.; et al. GCN2 eIF2 Kinase Promotes Prostate Cancer by Maintaining Amino Acid Homeostasis. eLife 2022, 11, e81083. [Google Scholar] [CrossRef]
Figure 2. The mechanism of amino acid signal sensing in PCa. PCa cells transport amino acids through various membrane transporters such as LAT1, LAT3 and ASCT2. Leucine, glutamine and arginine can regulate the mTORC1 signalling pathway via distinct mechanisms. Amino acid deprivation or the reduced activity of ARSs can stimulate GCN2, leading to the phosphorylation of eIF2α (eukaryotic translation initiation factor 2α) and the subsequent upregulation of ATF4 (Activating Transcription Factor 4) expression.
Figure 2. The mechanism of amino acid signal sensing in PCa. PCa cells transport amino acids through various membrane transporters such as LAT1, LAT3 and ASCT2. Leucine, glutamine and arginine can regulate the mTORC1 signalling pathway via distinct mechanisms. Amino acid deprivation or the reduced activity of ARSs can stimulate GCN2, leading to the phosphorylation of eIF2α (eukaryotic translation initiation factor 2α) and the subsequent upregulation of ATF4 (Activating Transcription Factor 4) expression.
Ijms 26 00776 g002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Yao, P.; Cao, S.; Zhu, Z.; Wen, Y.; Guo, Y.; Liang, W.; Xie, J. Cellular Signaling of Amino Acid Metabolism in Prostate Cancer. Int. J. Mol. Sci. 2025, 26, 776. https://doi.org/10.3390/ijms26020776

AMA Style

Yao P, Cao S, Zhu Z, Wen Y, Guo Y, Liang W, Xie J. Cellular Signaling of Amino Acid Metabolism in Prostate Cancer. International Journal of Molecular Sciences. 2025; 26(2):776. https://doi.org/10.3390/ijms26020776

Chicago/Turabian Style

Yao, Ping, Shiqi Cao, Ziang Zhu, Yunru Wen, Yawen Guo, Wenken Liang, and Jianling Xie. 2025. "Cellular Signaling of Amino Acid Metabolism in Prostate Cancer" International Journal of Molecular Sciences 26, no. 2: 776. https://doi.org/10.3390/ijms26020776

APA Style

Yao, P., Cao, S., Zhu, Z., Wen, Y., Guo, Y., Liang, W., & Xie, J. (2025). Cellular Signaling of Amino Acid Metabolism in Prostate Cancer. International Journal of Molecular Sciences, 26(2), 776. https://doi.org/10.3390/ijms26020776

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop